248 related articles for article (PubMed ID: 34016561)
1. Ibudilast (MN-166) in amyotrophic lateral sclerosis- an open label, safety and pharmacodynamic trial.
Babu S; Hightower BG; Chan J; Zürcher NR; Kivisäkk P; Tseng CJ; Sanders DL; Robichaud A; Banno H; Evora A; Ashokkumar A; Pothier L; Paganoni S; Chew S; Dojillo J; Matsuda K; Gudesblatt M; Berry JD; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2021; 30():102672. PubMed ID: 34016561
[TBL] [Abstract][Full Text] [Related]
2. Moving Toward Multicenter Therapeutic Trials in Amyotrophic Lateral Sclerosis: Feasibility of Data Pooling Using Different Translocator Protein PET Radioligands.
Van Weehaeghe D; Babu S; De Vocht J; Zürcher NR; Chew S; Tseng CJ; Loggia ML; Koole M; Rezaei A; Schramm G; Van Damme P; Hooker JM; Van Laere K; Atassi N
J Nucl Med; 2020 Nov; 61(11):1621-1627. PubMed ID: 32169920
[TBL] [Abstract][Full Text] [Related]
3. Integrated imaging of [
Ratai EM; Alshikho MJ; Zürcher NR; Loggia ML; Cebulla CL; Cernasov P; Reynolds B; Fish J; Seth R; Babu S; Paganoni S; Hooker JM; Atassi N
Neuroimage Clin; 2018; 20():357-364. PubMed ID: 30112276
[TBL] [Abstract][Full Text] [Related]
4. MN-166 (ibudilast) in amyotrophic lateral sclerosis in a Phase IIb/III study: COMBAT-ALS study design.
Oskarsson B; Maragakis N; Bedlack RS; Goyal N; Meyer JA; Genge A; Bodkin C; Maiser S; Staff N; Zinman L; Olney N; Turnbull J; Brooks BR; Klonowski E; Makhay M; Yasui S; Matsuda K
Neurodegener Dis Manag; 2021 Dec; 11(6):431-443. PubMed ID: 34816762
[TBL] [Abstract][Full Text] [Related]
5. Integrated magnetic resonance imaging and [
Alshikho MJ; Zürcher NR; Loggia ML; Cernasov P; Reynolds B; Pijanowski O; Chonde DB; Izquierdo Garcia D; Mainero C; Catana C; Chan J; Babu S; Paganoni S; Hooker JM; Atassi N
Ann Neurol; 2018 Jun; 83(6):1186-1197. PubMed ID: 29740862
[TBL] [Abstract][Full Text] [Related]
6. Neurofilament light chain in a phase 2 clinical trial of ibudilast in progressive multiple sclerosis.
Fox RJ; Raska P; Barro C; Karafa M; Konig V; Bermel RA; Chase M; Coffey CS; Goodman AD; Klawiter EC; Naismith RT; Kuhle J
Mult Scler; 2021 Nov; 27(13):2014-2022. PubMed ID: 33635141
[TBL] [Abstract][Full Text] [Related]
7. Phase 1b dose-escalation, safety, and pharmacokinetic study of IC14, a monoclonal antibody against CD14, for the treatment of amyotrophic lateral sclerosis.
Henderson RD; Agosti JM; McCombe PA; Thorpe K; Heggie S; Heshmat S; Appleby MW; Ziegelaar BW; Crowe DT; Redlich GL
Medicine (Baltimore); 2021 Oct; 100(42):e27421. PubMed ID: 34678870
[TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of bosutinib in patients with amyotrophic lateral sclerosis (iDReAM study): A multicentre, open-label, dose-escalation phase 1 trial.
Imamura K; Izumi Y; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Egawa N; Ayaki T; Oki R; Fujita K; Uozumi R; Morinaga A; Hirohashi T; Fujii Y; Yamamoto T; Tatebe H; Tokuda T; Takahashi N; Morita S; Takahashi R; Inoue H
EClinicalMedicine; 2022 Nov; 53():101707. PubMed ID: 36467452
[TBL] [Abstract][Full Text] [Related]
9. A Phase 1 study of GDC-0134, a dual leucine zipper kinase inhibitor, in ALS.
Katz JS; Rothstein JD; Cudkowicz ME; Genge A; Oskarsson B; Hains AB; Chen C; Galanter J; Burgess BL; Cho W; Kerchner GA; Yeh FL; Ghosh AS; Cheeti S; Brooks L; Honigberg L; Couch JA; Rothenberg ME; Brunstein F; Sharma KR; van den Berg L; Berry JD; Glass JD
Ann Clin Transl Neurol; 2022 Jan; 9(1):50-66. PubMed ID: 35014217
[TBL] [Abstract][Full Text] [Related]
10. Longitudinal course of neurofilament light chain levels in amyotrophic lateral sclerosis-insights from a completed randomized controlled trial with rasagiline.
Witzel S; Statland JM; Steinacker P; Otto M; Dorst J; Schuster J; Barohn RJ; Ludolph AC
Eur J Neurol; 2024 Mar; 31(3):e16154. PubMed ID: 37975796
[TBL] [Abstract][Full Text] [Related]
11. Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis - Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial).
Morimoto S; Takahashi S; Fukushima K; Saya H; Suzuki N; Aoki M; Okano H; Nakahara J
Regen Ther; 2019 Dec; 11():143-166. PubMed ID: 31384636
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Safety and Clinical Effects of a Muse Cell-Based Product in Patients With Amyotrophic Lateral Sclerosis: Results of a Phase 2 Clinical Trial.
Yamashita T; Nakano Y; Sasaki R; Tadokoro K; Omote Y; Yunoki T; Kawahara Y; Matsumoto N; Taira Y; Matsuoka C; Morihara R; Abe K
Cell Transplant; 2023; 32():9636897231214370. PubMed ID: 38014622
[TBL] [Abstract][Full Text] [Related]
14. Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.
Camu W; Mickunas M; Veyrune JL; Payan C; Garlanda C; Locati M; Juntas-Morales R; Pageot N; Malaspina A; Andreasson U; Kirby J; Suehs C; Saker S; Masseguin C; De Vos J; Zetterberg H; Shaw PJ; Al-Chalabi A; Leigh PN; Tree T; Bensimon G
EBioMedicine; 2020 Sep; 59():102844. PubMed ID: 32651161
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
;
Lancet Neurol; 2017 Jul; 16(7):505-512. PubMed ID: 28522181
[TBL] [Abstract][Full Text] [Related]
16. Induced pluripotent stem cell-based Drug Repurposing for Amyotrophic lateral sclerosis Medicine (iDReAM) study: protocol for a phase I dose escalation study of bosutinib for amyotrophic lateral sclerosis patients.
Imamura K; Izumi Y; Banno H; Uozumi R; Morita S; Egawa N; Ayaki T; Nagai M; Nishiyama K; Watanabe Y; Hanajima R; Oki R; Fujita K; Takahashi N; Ikeda T; Shimizu A; Morinaga A; Hirohashi T; Fujii Y; Takahashi R; Inoue H
BMJ Open; 2019 Dec; 9(12):e033131. PubMed ID: 31796494
[TBL] [Abstract][Full Text] [Related]
17. A pilot trial of RNS60 in amyotrophic lateral sclerosis.
Paganoni S; Alshikho MJ; Luppino S; Chan J; Pothier L; Schoenfeld D; Andres PL; Babu S; Zürcher NR; Loggia ML; Barry RL; Luotti S; Nardo G; Trolese MC; Pantalone S; Bendotti C; Bonetto V; De Marchi F; Rosen B; Hooker J; Cudkowicz M; Atassi N
Muscle Nerve; 2019 Mar; 59(3):303-308. PubMed ID: 30458059
[TBL] [Abstract][Full Text] [Related]
18. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28.
Zürcher NR; Loggia ML; Lawson R; Chonde DB; Izquierdo-Garcia D; Yasek JE; Akeju O; Catana C; Rosen BR; Cudkowicz ME; Hooker JM; Atassi N
Neuroimage Clin; 2015; 7():409-14. PubMed ID: 25685708
[TBL] [Abstract][Full Text] [Related]
19. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial.
Ljubenkov PA; Edwards L; Iaccarino L; La Joie R; Rojas JC; Koestler M; Harris B; Boeve BF; Borroni B; van Swieten JC; Grossman M; Pasquier F; Frisoni GB; Mummery CJ; Vandenberghe R; Le Ber I; Hannequin D; McGinnis SM; Auriacombe S; Onofrj M; Goodman IJ; Riordan HJ; Wisniewski G; Hesterman J; Marek K; Haynes BA; Patzke H; Koenig G; Hilt D; Moebius H; Boxer AL
JAMA Netw Open; 2021 Sep; 4(9):e2125584. PubMed ID: 34559230
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis: Neurofilament Light Chain Levels in Definite Subtypes of Disease.
Gaiani A; Martinelli I; Bello L; Querin G; Puthenparampil M; Ruggero S; Toffanin E; Cagnin A; Briani C; Pegoraro E; Sorarù G
JAMA Neurol; 2017 May; 74(5):525-532. PubMed ID: 28264096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
